| 货号 | MAB254-500 |
| 别名 | CXCL5; ENA-78 |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) Immunohistochemistry(8-25 µg/mL) |
| 目标/特异性 | Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) CXCL1, 2, 3, 8, 10, or recombinant mouse CXCL2 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Immunohistochemistry: 8-25 µg/mL Neutralization: Measured by its ability to neutralize CXCL5/ENA‑78-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 3-15 µg/mL in the presence of 0.03 µg/mL Recombinant Human CXCL5/ENA‑78. |
| 来源 | Monoclonal Mouse IgG1 Clone # 33160 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 6374 (Human) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. | |
| 纯化方式 | Protein A or G purified from ascites |
| 免疫原 | E. coli-derived recombinant human CXCL5/ENA-78 Ala37-Asn114 (predicted) Accession # P42830 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | CXCL5, also known as epithelial cell-derived-neutrophil-activating-peptide (ENA78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR- CXC chemokines which are angiostatic. Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP2, and CXCL8/IL8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. Full length CXCL5 (78 aa) is trimmed at the N-terminal end by Cathepsin G and chymotrypsin to ENA74 (74 aa) and ENA70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 exerts its effects primarily through interactions with CXCR2. It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
Chemotaxis Induced by CXCL5/ENA‑78 and Neutralization by Human CXCL5/ENA‑78 Antibody. Recombinant Human CXCL5/ENA‑78 (Catalog # 254‑XB) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL5/ENA‑78 (0.03 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL5/ENA‑78 Monoclonal Antibody (Catalog # MAB254). The ND50 is typically 3‑15 µg/mL. |
